A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival (2015) Ugurel S, Loquai C, Kaehler K, Hassel J, Berking C, Zimmer L, Haubitz I, et al. Journal article Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project+ (2015) Kramar A, Negrier S, Sylvester R, Joniau S, Mulders P, Powles T, Bex A, et al. Journal article Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients (2015) Hecht M, Zimmer L, Loquai C, Weishaupt C, Gutzmer R, Schuster B, Gleisner S, et al. Journal article Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy (2015) Lindner JL, Loibl S, Denkert C, Ataseven B, Fasching P, Pfitzner BM, Gerber B, et al. Journal article Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)+ (2014) Von Minckwitz G, Loibl S, Untch M, Eidtmann H, Rezai M, Fasching P, Tesch H, et al. Journal article Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial (2014) Leyvraz S, Piperno-Neumann S, Suciu S, Baurain JF, Zdzienicki M, Testori A, Marshall E, et al. Journal article Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine (2014) Grob JJ, Amonkar MM, Martin-Algarra S, Demidov LV, Goodman V, Grotzinger K, Haney P, et al. Journal article Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression (2014) Nitz U, Gluz O, Huober J, Kreipe HH, Kates RE, Hartmann A, Erber R, et al. Journal article Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro) (2014) Von Minckwitz G, Rezai M, Fasching P, Huober J, Tesch H, Bauerfeind I, Hilfrich J, et al. Journal article Personalized surgical therapy (2012) Tonn JC, Thon N, Schnell O, Kreth FW Journal article